We have located links that may give you full text access.
JOURNAL ARTICLE
OBSERVATIONAL STUDY
[Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products].
Annales Pharmaceutiques Françaises 2018 January
OBJECTIVES: To evaluate the economic impact of future prescriptions of etanercept and adalimumab biosimilars at the territorial scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products.
METHODS: Determination of the number and status of patients (naive or in continuation of treatment) from the National Database "Datamart de Consommation Inter-Régimes" of health insurance, concerned by a dispensation in a pharmacy of etanercept or adalimumab in 2015. Calculation of potential savings in case of biosimilar requirements according to 3 hypotheses: 63% (rate observed in a previous study) of initiations are treated with biosimiliaries and the others by princeps (H1 ); all initiations under biosimilars and continuation therapy with the princeps (H2 ) or all patients are treated with biosimilars (H3 ).
RESULTS: The annual savings are estimated at 237,000 € with the H1 hypothesis. In the case of H2 , the expected savings would be 376,200 € per year. In the case of H3 , savings for the community could reach almost 1,282,800 € per year.
CONCLUSION: The arrival of biosimilars allows significant savings for medicines market. According to the French recommendations in 2016, the expected savings are between the H1 and H2 hypothesis. The rate of penetration of biosimilars depends on many factors such as the involvement of health professionals, patient adherence, or health authority recommendations.
METHODS: Determination of the number and status of patients (naive or in continuation of treatment) from the National Database "Datamart de Consommation Inter-Régimes" of health insurance, concerned by a dispensation in a pharmacy of etanercept or adalimumab in 2015. Calculation of potential savings in case of biosimilar requirements according to 3 hypotheses: 63% (rate observed in a previous study) of initiations are treated with biosimiliaries and the others by princeps (H1 ); all initiations under biosimilars and continuation therapy with the princeps (H2 ) or all patients are treated with biosimilars (H3 ).
RESULTS: The annual savings are estimated at 237,000 € with the H1 hypothesis. In the case of H2 , the expected savings would be 376,200 € per year. In the case of H3 , savings for the community could reach almost 1,282,800 € per year.
CONCLUSION: The arrival of biosimilars allows significant savings for medicines market. According to the French recommendations in 2016, the expected savings are between the H1 and H2 hypothesis. The rate of penetration of biosimilars depends on many factors such as the involvement of health professionals, patient adherence, or health authority recommendations.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app